Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?

Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.

Zacks Investment Research • Feb 13, 2026

Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Feb 13, 2026

Focus on These 5 Stocks That Recently Hiked Dividends

NTES joins four peers in lifting dividends as resilient markets, rate-cut hopes and volatility spur investors toward steady income plays.

Zacks Investment Research • Feb 13, 2026

Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Gilead Sciences Inc. (NASDAQ: GILD) posted upbeat fourth-quarter earnings but issued weak fiscal 2026 guidance on Tuesday.

Benzinga • Feb 11, 2026

Gilead Sciences Stock Surges to Record Highs Amid Bull Notes

Gilead Sciences Inc  (NASDAQ:GILD) stock is up 5.7%, hitting a record high of $155.56 at last glance, after the biopharmaceutical company announced a top- and bottom-line win for the fourth quarter.

Schaeffers Research • Feb 11, 2026

GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales

Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.

Zacks Investment Research • Feb 11, 2026

Gilead Sciences Stock Spikes After Q4 Results: Time to Buy?

Biotech leader Gilead Sciences (GILD) made headlines on Wednesday, with its stock spiking nearly 6% after delivering favorable Q4 results yesterday evening.

Zacks Investment Research • Feb 12, 2026

Gilead quarterly results beat Wall Street estimates

Gilead Sciences on Tuesday reported fourth-quarter sales and profit that came in slightly above Wall Street estimates, while its 2026 financial forecast was at the lower end of analysts' expectations.

Reuters • Feb 10, 2026

Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance

Gilead Sciences Inc. (NASDAQ: GILD) shares slipped in Tuesday's extended trading after the company released its fourth-quarter earnings report with weak fiscal 2026 guidance.

Benzinga • Feb 10, 2026

Will Gilead's Solid Fourth Quarter Be Enough To Shake Off Its Light Outlook?

Gilead Sciences cleanly beat fourth-quarter expectations late Tuesday, but Gilead stock could take a hit on its light guidance for 2026.

Investors Business Daily • Feb 10, 2026